RBEL1 is required for osteosarcoma cell proliferation via inhibiting retinoblastoma 1

Tang,Honghui; Ji,Feng; Sun,Jin; Xie,Yue; Xu,Yongyi; Yue,Haitao

doi:10.3892/mmr.2015.4670

RBEL1 is required for osteosarcoma cell proliferation via inhibiting retinoblastoma 1

Authors:
- Honghui Tang
- Feng Ji
- Jin Sun
- Yue Xie
- Yongyi Xu
- Haitao Yue
View Affiliations

Affiliations: Department of Orthopedics, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu 223300, P.R. China
Published online on: December 10, 2015 https://doi.org/10.3892/mmr.2015.4670
Pages: 1275-1280

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Osteosarcoma is the most common type of primary malignant tumor of the bone. However, mechanisms underlying osteosarcoma cell proliferation are poorly understood. The present study shows that RBEL1, a newly identified Rab‑like GTPase, may be a key regulator of osteosarcoma cell proliferation. Knockdown of RBEL1 in osteosarcoma cells resulted in impaired colony formation and cell proliferation. Cell cycle analysis suggested that RBEL1 depletion induced G1‑S arrest in osteosarcoma cells. Furthermore, it was demonstrated that retinoblastoma 1 (Rb) was upregulated and activated following RBEL1 knockdown. In addition, Rb inhibitory downstream targets, such as cyclin A2, cyclin D1, c‑Myc and cyclin‑dependent kinase 2, were downregulated. Rb knockdown reversed RBEL1 depletion‑induced tumor suppressive effects. In conclusion, the present results suggest that RBEL1 modulates cell proliferation and G1‑S transition by inhibiting Rb in osteosarcoma. These results suggest a potential therapeutic target in osteosarcoma.

View Figures

View References

1	Moore DD and Luu HH: Osteosarcoma. Cancer Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Kansara M, Teng MW, Smyth MJ and Thomas DM: Translational biology of osteosarcoma. Nat Rev Cancer. 14:722–735. 2014. View Article : Google Scholar : PubMed/NCBI
4	Nakamura T, Matsumine A, Matsubara T, Asamuma K, Niimi R, Uchida A and Sudo A: Retrospective analysis of metastatic sarcoma patients. Oncol Lett. 2:315–318. 2011.PubMed/NCBI
5	Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 9:422–441. 2004. View Article : Google Scholar : PubMed/NCBI
6	Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003. View Article : Google Scholar : PubMed/NCBI
7	Stenmark H: Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 10:513–525. 2009. View Article : Google Scholar : PubMed/NCBI
8	Montalbano J, Jin W, Sheikh MS and Huang Y: RBEL1 is a novel gene that encodes a nucleocytoplasmic Ras superfamily GTP-binding protein and is overexpressed in breast cancer. J Biol Chem. 282:37640–37649. 2007. View Article : Google Scholar : PubMed/NCBI
9	Montalbano J, Lui K, Sheikh MS and Huang Y: Identification and characterization of RBEL1 subfamily of GTPases in the Ras superfamily involved in cell growth regulation. J Biol Chem. 284:18129–18142. 2009. View Article : Google Scholar : PubMed/NCBI
10	Hochegger H, Takeda S and Hunt T: Cyclin-dependent kinases and cell-cycle transitions: Does one fit all? Nat Rev Mol Cell Biol. 9:910–916. 2008. View Article : Google Scholar : PubMed/NCBI
11	Burkhart DL and Sage J: Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer. 8:671–682. 2008. View Article : Google Scholar : PubMed/NCBI
12	Classon M and Harlow E: The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer. 2:910–917. 2002. View Article : Google Scholar : PubMed/NCBI
13	Travis LB, Demark Wahnefried W, Allan JM, Wood ME and Ng AK: Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 10:289–301. 2013. View Article : Google Scholar : PubMed/NCBI
14	Barcellos-Hoff MH: Does microenvironment contribute to the etiology of estrogen receptor-negative breast cancer? Clin Cancer Res. 19:541–548. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
16	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
17	Gupta SC, Kim JH, Prasad S and Aggarwal BB: Regulation of survival, proliferation, invasion, angiogenesis and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev. 29:405–434. 2010. View Article : Google Scholar : PubMed/NCBI
18	Fritz V and Fajas L: Metabolism and proliferation share common regulatory pathways in cancer cells. Oncogene. 29:4369–4377. 2010. View Article : Google Scholar : PubMed/NCBI
19	Whitfield ML, George LK, Grant GD and Perou CM: Common markers of proliferation. Nat Rev Cancer. 6:99–106. 2006. View Article : Google Scholar : PubMed/NCBI
20	Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death and tumorigenesis. Br J Cancer. 94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
21	Deng H, Cheng Y, Guo Z, Zhang F, Lu X, Feng L, Wang X and Xu Z: Overexpression of CyclinA2 ameliorates hypoxia-impaired proliferation of cardiomyocytes. Exp Ther Med. 8:1513–1517. 2014.PubMed/NCBI
22	Chen G, Wang H, Xie S, Ma J and Wang G: STAT1 negatively regulates hepatocellular carcinoma cell proliferation. Oncol Rep. 29:2303–2310. 2013.PubMed/NCBI
23	Bertoli C, Skotheim JM and de Bruin RA: Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 14:518–528. 2013. View Article : Google Scholar : PubMed/NCBI
24	Tian Y, Wan H and Tan G: Cell cycle-related kinase in carcinogenesis. Oncol Lett. 4:601–606. 2012.PubMed/NCBI
25	Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166. 2009. View Article : Google Scholar : PubMed/NCBI
26	Zhang L, Zhou Q, Zhang N, Li W, Ying M, Ding W, Yang B and He Q: E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα. Cell Cycle. 13:1277–1287. 2014. View Article : Google Scholar :
27	Wang XH, Cai P, Wang MH and Wang Z: MicroRNA-25 promotes osteosarcoma cell proliferation by targeting the cell cycle inhibitor p27. Mol Med Rep. 10:855–859. 2014.PubMed/NCBI
28	Dick FA and Rubin SM: Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol. 14:297–306. 2013. View Article : Google Scholar : PubMed/NCBI
29	Chen HZ, Tsai SY and Leone G: Emerging roles of E2Fs in cancer: An exit from cell cycle control. Nat Rev Cancer. 9:785–797. 2009. View Article : Google Scholar : PubMed/NCBI
30	Prior IA, Lewis PD and Mattos C: A comprehensive survey of Ras mutations in cancer. Cancer Res. 72:2457–2467. 2012. View Article : Google Scholar : PubMed/NCBI